eIF4E binding peptides

• US 9,018,348 B2
• Filed: 04/27/2011
• Issued: 04/28/2015
• Est. Priority Date: 04/27/2010
• Status: Active Grant

• Current Assignee: Agency For Science Technology and Research (Government of Singapore)
• Original Assignee: Agency For Science Technology and Research (Government of Singapore)
• Inventors: Brown, Christopher John, Chia, Cheng San Brian
• Primary Examiner(s): Kolker, Daniel E
• Assistant Examiner(s): Dutt, Aditi
• Application Number:
  US13/695,011
• Publication Number:
  US 20130130989A1
• Time in Patent Office: 1,462 Days
• Field of Search: None
• US Class Current: 530/300
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: C07K 14/4705 stimulating, promoting or activating activity
• CPC Class Codes: C07K 2319/10 containing a tag for extracellular membrane crossing, e.g. TAT or VP22
• CPC Class Codes: C07K 7/08 having 12 to 20 amino acids gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68

Abstract

The present invention relates to modified eIF4G1 peptides, uses thereof and pharmaceutical compositions comprising the modified eIF4G1 peptides.

Claims

1. A modified eukaryotic translation initiation factor 4 gamma 1 (eIF4G1) peptide derived from the human eIF4G1 protein with the amino acid sequence SEQ ID NO. 8, wherein the peptide has been modified to stabilize the α

-helix wherein the peptide comprises the amino acid sequence KKRYDREFLL*FQF (SEQ ID NO;

     10), wherein * represents a non-natural amino acid.

2. The modified eIF4G1 peptide of claim 1, wherein the modified eIF4G1 peptide comprises a sequence selected from the group consisting of Linker-KKRYDREFLL*FQF(SEQ ID NO:

10)-NH2 and KKRYDREFLL*FQF(SEQ ID NO;

     10)-NH2.

3. The modified eIF4G1 peptide of claim 1, wherein the modified peptide comprises a protection group.

4. The modified eIF4G1 peptide of claim 3, wherein the protection group is an acyl or acetyl group.

5. The modified eIF4G1 peptide of claim 1, wherein the modified peptide comprises capping groups at the N-terminus and/or the C-terminus.

6. The modified eIF4G1 peptide of claim 1, wherein the non-natural amino acid is a cycloalkane derivative.

7. The modified eIF4G1 peptide of claim 6, wherein the cycloalkane derivative is selected from the group consisting of 1-aminocyclopentanoic acid, 1-aminocyclohexanoic acid, β

-cyclohexylalanine, an α

-(1-carboxycyclopentyl)glycine, 1-aminocyclopropanoic acid, 1-amino cyclobutanoic acid and aminomethylcyclohexanoic acid.

8. The modified eIF4G1 peptide of claim 1, wherein the modified eIF4G1 peptide further comprises an N-terminus which is modified.

9. The modified eIF4G1 peptide of claim 1, wherein the modified eIF4G1 peptide further comprises a C-terminus which is modified.